(Q25257471)

English

Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

0 references

Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

0 references

0 references

author name string

Hong Liu-Seifert

1

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

David H Adams

2

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Bruce J Kinon

3

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

language of work or name

0 references

publication date

23 December 2005

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

1

0 references

21

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1327673

7 April 2017

Determinants of medication compliance in schizophrenia: empirical and clinical findings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1327673

7 April 2017

How often do patients with psychosis fail to adhere to treatment programmes? A systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1327673

28 September 2017

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1327673

28 September 2017

An economic review of compliance with medication therapy in the treatment of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1327673

28 September 2017

Predictors of noncompliance in patients with schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1327673

28 September 2017

Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1327673

28 September 2017

Management of treatment resistance in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1327673

28 September 2017

Dropout rates in randomised antipsychotic drug trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1327673

28 September 2017

Treatment-resistant schizophrenia: reviewing the options and identifying the way forward.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1327673

28 September 2017

Adherence to antipsychotic medications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1327673

28 September 2017

Compliance with medication regimens for mental and physical disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1327673

28 September 2017

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1327673

28 September 2017

Neuroleptics and the Natural Course of Schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1327673

28 September 2017

Sociobehavioral Determinants of Compliance with Health and Medical Care Recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1327673

28 September 2017

Treatment of neuroleptic-resistant schizophrenic relapse.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1327673

31 May 2018

Patients' opinions concerning side effects of depot neuroleptics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1327673

31 May 2018

Factors influencing relapse in the long-term course of schizophrenia.

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-3-21

21 January 2018

Dropout rates with olanzapine or risperidone: a multi-centre observational study

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-3-21

21 January 2018

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-3-21

21 January 2018

Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-3-21

21 January 2018

Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-3-21

21 January 2018

Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence

1 reference

https://pubmed.ncbi.nlm.nih.gov/16375765

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuroleptic treatment and prediction of response

1 reference

https://pubmed.ncbi.nlm.nih.gov/16375765

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Special Issue: Abstracts of the XX International Congress on Schizophrenia Research

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-3-21

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1186/1741-7015-3-21

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Dimensions Publication ID

0 references

release_xgbsvdevpfafpifmyofpfy2x5q

1 reference

https://api.fatcat.wiki/v0/release/xgbsvdevpfafpifmyofpfy2x5q

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q25257471&oldid=2177069942"